- US-listed companies
- Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc.SYRS
Market cap
$41.01M
P/E ratio
Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
Revenue | - | - | 2 | 2 | 15 | 24 | 15 |
Research and development | 38 | 42 | 50 | 58 | 76 | 100 | 112 |
General and administrative | 10 | 14 | 16 | 21 | 21 | 23 | 29 |
Transaction related expenses | - | - | - | - | - | - | 10 |
Total operating expenses | 48 | 56 | 66 | 80 | 97 | 123 | 151 |
Loss from operations | -48 | -55 | -64 | -78 | -82 | -99 | -136 |
Interest income | - | - | - | - | 0 | 0 | 2 |
Interest expense | - | - | - | - | 2 | 4 | 4 |
Change in fair value of warrant liabilities | - | - | - | - | 0 | -17 | -43 |
Net loss applicable to common stockholders | -51 | -54 | -62 | -75 | -84 | -87 | -95 |
Net loss per share applicable to common stockholders - basic | - | - | - | - | - | - | -7.49 |
Net loss per share applicable to common stockholders - diluted | - | - | - | - | - | - | -7.49 |